197 related articles for article (PubMed ID: 23591112)
1. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
[TBL] [Abstract][Full Text] [Related]
2. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3416-20. PubMed ID: 23591110
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.
Cole DC; Gross JL; Comery TA; Aschmies S; Hirst WD; Kelley C; Kim JI; Kubek K; Ning X; Platt BJ; Robichaud AJ; Solvibile WR; Stock JR; Tawa G; Williams MJ; Ellingboe JW
Bioorg Med Chem Lett; 2010 Feb; 20(3):1237-40. PubMed ID: 20042333
[TBL] [Abstract][Full Text] [Related]
4. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Stocking EM; Aluisio L; Atack JR; Bonaventure P; Carruthers NI; Dugovic C; Everson A; Fraser I; Jiang X; Leung P; Lord B; Ly KS; Morton KL; Nepomuceno D; Shah CR; Shelton J; Soyode-Johnson A; Letavic MA
Bioorg Med Chem Lett; 2010 May; 20(9):2755-60. PubMed ID: 20382018
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
[TBL] [Abstract][Full Text] [Related]
6. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
7. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.
de Lera Ruiz M; Zheng J; Berlin MY; McCormick KD; Aslanian RG; West R; Hwa J; Lachowicz J; van Heek M
Bioorg Med Chem Lett; 2013 Nov; 23(21):6004-9. PubMed ID: 24035485
[TBL] [Abstract][Full Text] [Related]
8. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile.
Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2013 May; 23(9):2548-54. PubMed ID: 23535326
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L
ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
[TBL] [Abstract][Full Text] [Related]
10. A new family of H3 receptor antagonists based on the natural product Conessine.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Sengupta D; Duffield JJ; Semple G; Webb RR; Sage C; Ren A; Pereira G; Knudsen J; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Whelan K; Grottick AJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1490-4. PubMed ID: 18194865
[TBL] [Abstract][Full Text] [Related]
11. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
[No Abstract] [Full Text] [Related]
12. Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.
Gao Z; Hurst WJ; Czechtizky W; Hall D; Moindrot N; Nagorny R; Pichat P; Stefany D; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Dec; 23(23):6269-73. PubMed ID: 24139584
[TBL] [Abstract][Full Text] [Related]
13. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.
Brown DG; Bernstein PR; Griffin A; Wesolowski S; Labrecque D; Tremblay MC; Sylvester M; Mauger R; Edwards PD; Throner SR; Folmer JJ; Cacciola J; Scott C; Lazor LA; Pourashraf M; Santhakumar V; Potts WM; Sydserff S; Giguère P; Lévesque C; Dasser M; Groblewski T
J Med Chem; 2014 Feb; 57(3):733-58. PubMed ID: 24410637
[TBL] [Abstract][Full Text] [Related]
14. Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.
Nirogi R; Shinde A; Tiriveedhi V; Kota L; Saraf SK; Badange RK; Mohammed AR; Subramanian R; Muddana N; Bhyrapuneni G; Abraham R
Eur J Med Chem; 2016 Jan; 108():655-662. PubMed ID: 26731168
[TBL] [Abstract][Full Text] [Related]
15. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882
[TBL] [Abstract][Full Text] [Related]
16. From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Dunn D; Raddatz R; Ator MA; Bacon ER; Chatterjee S
Chem Biol Drug Des; 2013 Mar; 81(3):433-5. PubMed ID: 23205610
[TBL] [Abstract][Full Text] [Related]
17. The discovery of potent selective NPY Y(2) antagonists.
Chai W; Wong VD; Nepomuceno D; Bonaventure P; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2013 Jul; 23(14):4141-4. PubMed ID: 23756063
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.
Josef KA; Aimone LD; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jun; 22(12):4198-202. PubMed ID: 22617490
[TBL] [Abstract][Full Text] [Related]
19. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
[TBL] [Abstract][Full Text] [Related]
20. Fluorinated non-imidazole histamine H3 receptor antagonists.
Isensee K; Amon M; Garlapati A; Ligneau X; Camelin JC; Capet M; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2009 Apr; 19(8):2172-5. PubMed ID: 19286376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
